643 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00773 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.1 µMo/L |
| dbacp00774 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 4.3 µMo/L |
| dbacp00775 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5 µMo/L |
| dbacp00776 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 6.4 µMo/L |
| dbacp00777 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 7.5 µMo/L |
| dbacp00778 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.4 µMo/L |
| dbacp00779 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 5.2 µMo/L |
| dbacp00780 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.8 µMo/L |
| dbacp00781 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.7 µMo/L |
| dbacp00782 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 8.7 µMo/L |
| dbacp00783 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.2 µMo/L |
| dbacp00784 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 4.3 µMo/L |
| dbacp00785 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 6.4 µMo/L |
| dbacp00786 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.1 µMo/L |
| dbacp00787 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.4 µMo/L |
| dbacp00788 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2 µMo/L |
| dbacp00789 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.2 µMo/L |
| dbacp00790 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 7.2 µMo/L |
| dbacp00791 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.7 µMo/L |
| dbacp00792 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 3.5 µMo/L |
| dbacp00793 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 5.5 µMo/L |
| dbacp00794 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.7 µMo/L |
| dbacp00795 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.6 µMo/L |
| dbacp00796 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.2 µMo/L |
| dbacp00797 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.7 µMo/L |
| dbacp00798 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 6.5 µMo/L |
| dbacp00799 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.1 µMo/L |
| dbacp00800 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 5 µMo/L |
| dbacp00801 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 9.8 µMo/L |
| dbacp00802 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.9 µMo/L |
| dbacp00803 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 7.8 µMo/L |
| dbacp00804 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.3 µMo/L |
| dbacp00989 | Agelaia-MPI | INWLKLGKAIIDAL | Artistic wasp | Antinociceptive activity; Membrane disruption | Not specified | MM96L | Melanoma | CC50 : <10 µM |
| dbacp00990 | Agelaia-MPI | INWLKLGKAIIDAL | Artistic wasp | Antinociceptive activity; Membrane disruption | Not specified | HCT116 | Colorectal cancer | CC50 : >32 µM |
| dbacp01160 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | NCIeH157 | Human squamous carcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01161 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | NCIeH838 | Human Lung adenocarcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01162 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | PC-3 | androgen-independent Prostate adenocarcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01163 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | MCF-7 | Human breast carcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01164 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | U251 | Human glioblastoma | IC50 : 0.83 - 2.0 μM |
| dbacp01190 | Ascaphin-8 | GFKDLLKGAAKALVKTVLF | Coastal Tailed Frog, Pacific Northwest, USA, North America | Membrane disruption and cell lysis | Lactate dehydrogenase assay | HepG2 | Liver | LD50 : 20 µM |
| dbacp01251 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01252 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01253 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01254 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01255 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10-100 µM |
| dbacp01256 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10-100 µM |
| dbacp01257 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01258 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01259 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01260 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01261 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01262 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01263 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01264 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10-100 µM |
| dbacp01265 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10-100 µM |
| dbacp01266 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01267 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01268 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01269 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01270 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01271 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01272 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01273 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01274 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01275 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01276 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01277 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01278 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01279 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01280 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01281 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01282 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01283 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01284 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01285 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01286 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01287 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01288 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01289 | Aurein-1.1 | GLFDIIKKIAESI | Southern bell frog | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01290 | Aurein-1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01305 | Aurein-2.2 [Cleaved into: Aurein-2.2.1] | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGALGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Colorectal cancer | LC50 : 10-5 - 10-4 M |
| dbacp01306 | Aurein-2.3 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNGEDEDENEAANHEEGSEEKRGLFDIVKKVVGAIGSLGKRNDVE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Prostate cancer | LC50 : 10-5 - 10-4 M |
| dbacp01338 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Leukaemia | LC50 : 10-5 - 10-4 M |
| dbacp01339 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Lung cancer | LC50 : 10-5 - 10-4 M |
| dbacp01340 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Colon cancer | LC50 : 10-5 - 10-4 M |
| dbacp01341 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Prostate cancer | LC50 : 10-5 - 10-4 M |
| dbacp01342 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Breast cancer | LC50 : 10-5 - 10-4 M |
| dbacp01343 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Leukaemia | LC50 : 10-5 - 10-4 M |
| dbacp01345 | Aurein-2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Membrane disruption | Not specified | Not specified | Not specified | LC50 : 10-5 - 10-4 M |
| dbacp01367 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKIAGHIAGSIGKKR | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Lung cancer | LC50 : 10-5 - 10-4 M |
| dbacp01405 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01406 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01407 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01408 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01409 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01410 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01411 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01412 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01413 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01414 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01415 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01416 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01417 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01418 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01419 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01420 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01421 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01422 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01423 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01424 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01425 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01426 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01427 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01428 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01429 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01430 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01431 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01941 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | H157 | Lung cancer | IC50 : 3.37 to 5.87 µM |
| dbacp01942 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | PC-3 | Prostate cancer | IC50 : 3.37 to 5.87 µM |
| dbacp01943 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | HCT116 | Human colorectal cancer | IC50 : 3.37 to 5.87 µM |
| dbacp01944 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | U251MG | Human glioblastoma astrocytoma | IC50 : 3.37 to 5.87 µM |
| dbacp02160 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :10.6 ± 0.4 µM |
| dbacp02161 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :13.0 ± 1.0 µM |
| dbacp02162 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :12.1 ± 1.6 µM |
| dbacp02163 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :37 ± 4.3 µM |
| dbacp02164 | C7A | KILRGVAKKILRTFLRRISKDILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 10.6 ± 0.4 µM |
| dbacp02165 | C7A | KILRGVAKKILRTFLRRISKDILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.0 ± 1.0 µM |
| dbacp02166 | C7A | KILRGVAKKILRTFLRRISKDILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.1 ± 1.6 µM |
| dbacp02167 | C7A | KILRGVAKKILRTFLRRISKDILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 3.7 ± 4.3 µM |
| dbacp02181 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.4 ± 0.2 µM |
| dbacp02182 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 2.0 µM |
| dbacp02183 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.3 ± 0.5 µM |
| dbacp02184 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 1.0 µM |
| dbacp02185 | C7A-D21k | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.4 ± 0.2 µM |
| dbacp02186 | C7A-D21k | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 2.0 µM |
| dbacp02187 | C7A-D21k | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.3 ± 0.5 µM |
| dbacp02188 | C7A-D21k | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 1.0 µM |
| dbacp02202 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 7.5 ± 0.4 µM |
| dbacp02203 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.8 ± 2.0 µM |
| dbacp02204 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 9.3 ± 1.5 µM |
| dbacp02205 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | NK-2 variants | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.1 ± 0.9 µM |
| dbacp02206 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.8 ± 2.0 µM |
| dbacp02207 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 9.3 ± 1.5 µM |
| dbacp02208 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.1 ± 0.9 µM |
| dbacp02222 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 7.5 ± 0.4 µM |
| dbacp02286 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp02287 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02288 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp02289 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp02290 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp02291 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp02292 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp02306 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 20 µM approx. |
| dbacp02307 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 30 µM |
| dbacp02308 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 40 µM |
| dbacp02315 | Cationic Amphiphilic | GIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HeLa | Cervical cancer | IC50 : 160 µM |
| dbacp02316 | Cationic Amphiphilic | GIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HeLa | Cervical cancer | IC50 : 15 µM |
| dbacp02317 | Cationic Amphiphilic | GIIKKIIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HeLa | Pancreatic cancer | IC50 : 4 µM |
| dbacp02318 | Cationic Amphiphilic | GIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : >500 µM |
| dbacp02319 | Cationic Amphiphilic | GIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 25 µM |
| dbacp02320 | Cationic Amphiphilic | GIIKKIIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 10 µM |
| dbacp02326 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | WST-1 assay | 486P | Bladder cancer | IC50 : 251.47 µg/ml |
| dbacp02327 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | WST-1 assay | RT4 | Bladder cancer | IC50 : 231.26 µg/ml |
| dbacp02328 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | WST-1 assay | 647V | Bladder cancer | IC50 : 185.39 µg/ml |
| dbacp02329 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | WST-1 assay | J82 | Bladder cancer | IC50 : 212.07 µg/ml |
| dbacp02330 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | Cell viability assay | 486P | Bladder cancer | IC50 : 69.2 µg/ml |
| dbacp02331 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | Cell viability assay | RT4 | Bladder cancer | IC50 : 96.22 µg/ml |
| dbacp02332 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | Cell viability assay | 647V | Bladder cancer | IC50 : 28.74 µg/ml |
| dbacp02333 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | Cell viability assay | J82 | Bladder cancer | IC50 : 99.01 µg/ml |
| dbacp02334 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | LDH leakage assay | 486P | Bladder cancer | IC50 : 373.3/ µg/ml |
| dbacp02335 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | LDH leakage assay | RT4 | Bladder cancer | IC50 : 289.3 µg/ml |
| dbacp02336 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | LDH leakage assay | 647V | Bladder cancer | IC50 : 200.7 µg/ml |
| dbacp02337 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Silkmoth | Membrane disruption | LDH leakage assay | J82 | Bladder cancer | IC50 : 319.2 µg/ml |
| dbacp02345 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | WST-1 assay | 486P | Bladder cancer | IC50 : 161.76 µg/ml |
| dbacp02346 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | WST-1 assay | RT4 | Bladder cancer | IC50 : 184.81 µg/ml |
| dbacp02347 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | WST-1 assay | 647V | Bladder cancer | IC50 : 115.12 µg/ml |
| dbacp02348 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | WST-1 assay | J82 | Bladder cancer | IC50 : 97.93 µg/ml |
| dbacp02349 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | Cell viability assay | 486P | Bladder cancer | IC50 : 87.47 µg/ml |
| dbacp02350 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | Cell viability assay | RT4 | Bladder cancer | IC50 : 92.9 µg/ml |
| dbacp02351 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | Cell viability assay | 647V | Bladder cancer | IC50 : 61.86 µg/ml |
| dbacp02352 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | Cell viability assay | J82 | Bladder cancer | IC50 : 77.51 µg/ml |
| dbacp02353 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | LDH leakage assay | 486P | Bladder cancer | IC50 : 232.4 µg/ml |
| dbacp02354 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | LDH leakage assay | RT4 | Bladder cancer | IC50 : 240.4 µg/ml |
| dbacp02355 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | LDH leakage assay | 647V | Bladder cancer | IC50 : 181.1 µg/ml |
| dbacp02356 | Cecropin B | KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL | Chinese oak silk moth | Membrane disruption | LDH leakage assay | J82 | Bladder cancer | Cytotoxicity : 196.3 µg/ml |
| dbacp02612 | D-amino-acid oxidase | MHSQKRVVVLGSGVIGLSSALILARKGYSVHILARDLPEDVSSQTFASPWAGANWTPFMTLTDGPRQAKWEESTFKKWVELVPTGHAMWLKGTRRFAQNEDGLLGHWYKDITPNYRPLPSSECPPGAIGVTYDTLSVHAPKYCQYLARELQKLGATFERRTVTSLEQAFDGADLVVNATGLGAKSIAGIDDQAAEPIRGQTVLVKSPCKRCTMDSSDPASPAYIIPRPGGEVICGGTYGVGDWDLSVNPETVQRILKHCLRLDPTISSDGTIEGIEVLRHNVGLRPARRGGPRVEAERIVLPLDRTKSPLSLGRGSARAAKEKEVTLVHAYGFSSAGYQQSWGAAEDVAQLVDEAFQRYHGAARESKL | Not found | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp02620 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | 22RV1 | Prostate cancer | LC50 : 6 µMol/L |
| dbacp02621 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | CL-1 | Lung cancer | LC50 : 3 µMol/L |
| dbacp02622 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | MB-231 | Prostate cancer | LC50 : 3 µMol/L |
| dbacp02638 | Decoralin | SLLSLIRKLIT | Venom, solitary eumenine wasp | Cell membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp02651 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MDA-MB-435S | Lung cancer | MIC : 10−9 to 10−4 M |
| dbacp02652 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | H157 | Glioma | MIC : 10−9 to 10−4 M |
| dbacp02653 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02654 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MCF-7 | Breast cancer | MIC : 10−9 to 10−4 M |
| dbacp02727 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MDA-MB-435S | Lung cancer | MIC : 10−9 to 10−4 M |
| dbacp02728 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | H157 | Glioma | MIC : 10−9 to 10−4 M |
| dbacp02729 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02730 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MCF-7 | Breast cancer | MIC : 10−9 to 10−4 M |
| dbacp02744 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | At 10 µM 60% viablity |
| dbacp02745 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | At 10 µM 35-40% viablity |
| dbacp02787 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp02788 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02789 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp02790 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp02791 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp02792 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp02793 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp02794 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp02795 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02796 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp02797 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp02798 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp02799 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp02800 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp02919 | Esculentin-2CHa | GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC | Chiricahua leopard frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent cell viability assay | A549 cells | Lung adenocarcinoma | LC50 : 10μM |
| dbacp02921 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp02922 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02923 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp02924 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp02925 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp02926 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp02927 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp02929 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | NIH/3T3 | Cervical cancer | IC50 : 13 µM |
| dbacp02930 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | B16F10 | Leukemia | IC50 : 10.5 µM |
| dbacp02931 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | MCF | Murine Melanoma | IC50 : 13.7 µM |
| dbacp02932 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | HeLa | Breast cancer | IC50 :11.1 µM |
| dbacp02945 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | NIH/3T3 | Cervical cancer | IC50 : 13 µM |
| dbacp02946 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | B16F10 | Leukemia | IC50 : 10.5 µM |
| dbacp02947 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | MCF | Murine melanoma | IC50 : 13.7 µM |
| dbacp02948 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | HeLa | Breast cancer | IC50 : 11.1 µM |
| dbacp02958 | Figainin 2PL | FLGTVLKLGKAIAKTVVPMLTNAMQPKQ | Skin secretions, the bananatree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | A549 | Not found | LC50 : < 30 μM |
| dbacp02959 | Figainin 2PL | FLGTVLKLGKAIAKTVVPMLTNAMQPKQ | Skin secretions, the bananatree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | MDA-MB-231 | Not found | LC50 : < 30 μM |
| dbacp02960 | Figainin 2PL | FLGTVLKLGKAIAKTVVPMLTNAMQPKQ | Skin secretions, the bananatree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | HT30 | Not found | LC50 : < 30 μM |
| dbacp02972 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02973 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02974 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 27.00 µM |
| dbacp02975 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 26.70 µM |
| dbacp02976 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02977 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 27.39 µM |
| dbacp02978 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 27.39 µM |
| dbacp02979 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02980 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02981 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 27.00 µM |
| dbacp02982 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 26.70 µM |
| dbacp02983 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02984 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 27.39 µM |
| dbacp02985 | GA-K3 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 24.76 µM |
| dbacp02986 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02987 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02988 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp02989 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 22.51 µM |
| dbacp02990 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 :29.10 µM |
| dbacp02991 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 :22.25 µM |
| dbacp02992 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 :12.55 µM |
| dbacp02993 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02994 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02995 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.8 µM |
| dbacp02996 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 22.51 µM |
| dbacp02997 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 29.10 µM |
| dbacp02998 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 22.25 µM |
| dbacp02999 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 12.55 µM |
| dbacp03000 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03001 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03002 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 24.63 µM |
| dbacp03003 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 24.31 µM |
| dbacp03004 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03005 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.97 µM |
| dbacp03006 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03007 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03008 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03009 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 24.63 µM |
| dbacp03010 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 24.31 µM |
| dbacp03011 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03012 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.97 µM |
| dbacp03013 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03014 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 :22.59 µM |
| dbacp03015 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03016 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp03017 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 13.77 µM |
| dbacp03018 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03019 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.16 µM |
| dbacp03020 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp03021 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.59 µM |
| dbacp03022 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03023 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp03024 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 13.77 µM |
| dbacp03025 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03026 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.16 µM |
| dbacp03027 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp03055 | Geranylgeranyl transferase type-1 subunit beta | MAATEDDRLAGSGEGERLDFLRDRHVRFFQRCLQVLPERYSSLETSRLTIAFFALSGLDMLDSLDVVNKDDIIEWIYSLQVLPTEDRSNLDRCGFRGSSYLGIPFNPSKNPGTAHPYDSGHIAMTYTGLSCLIILGDDLSRVDKEACLAGLRALQLEDGSFCAVPEGSENDMRFVYCASCICYMLNNWSGMDMKKAISYIRRSMSYDNGLAQGAGLESHGGSTFCGIASLCLMGKLEEVFSEKELNRIKRWCIMRQQNGYHGRPNKPVDTCYSFWVGATLKLLKIFQYTNFEKNRNYILSTQDRLVGGFAKWPDSHPDALHAYFGICGLSLMEESGICKVHPALNVSTRTSERLRDLHQSWKTKDSKQCSDNVHISS | Rat | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp03073 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03074 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03075 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03076 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03077 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03078 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03079 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03298 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03299 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03300 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03301 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03302 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03303 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03304 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03309 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03310 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03311 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03312 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03313 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03314 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03315 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03349 | Hylin PL | FLGLIPALAGAIGNLIK | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | A549 | Not found | LC50 : < 30 μM |
| dbacp03350 | Hylin PL | FLGLIPALAGAIGNLIK | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | MDA-MB-231 | Not found | LC50 : < 30 μM |
| dbacp03351 | Hylin PL | FLGLIPALAGAIGNLIK | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | HT31 | Not found | LC50 : < 30 μM |
| dbacp03352 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | A549 | Lung cancer | LC50 : 2.5 ± 0.2 μM |
| dbacp03353 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | MDA-MB-231 | Breast cancer | LC50 : 9.0 ± 0.3 μM |
| dbacp03354 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | HT-29 | Colon cancer | LC50 : 9.7 ± 0.2 μM |
| dbacp03355 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | HepG2 | Liver cancer | LC50 : 22.5 ± 1.4 μM |
| dbacp03399 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03400 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03401 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03402 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03403 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03404 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03405 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03570 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03571 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03572 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03573 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03574 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03575 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 16.4 µMo/L |
| dbacp03576 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03577 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : > 83.6 µMo/L |
| dbacp03578 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03579 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03580 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03581 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03582 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03583 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 37.7 µMo/L |
| dbacp03584 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03585 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp03589 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 71 µMo/L |
| dbacp03590 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 59.8 µMo/L |
| dbacp03591 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 70.8 µMo/L |
| dbacp03592 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03593 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03594 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 15.6 µMo/L |
| dbacp03595 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 63.5 µMo/L |
| dbacp03596 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 64.7 µMo/L |
| dbacp03613 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 53 µMo/L |
| dbacp03614 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 58.7 µMo/L |
| dbacp03615 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 62.3 µMo/L |
| dbacp03616 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03617 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03618 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 14 µMo/L |
| dbacp03619 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 62.5 µMo/L |
| dbacp03620 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 58.6 µMo/L |
| dbacp03621 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03622 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03623 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >83.6 µMo/L |
| dbacp03624 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03625 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03626 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03627 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03628 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp03650 | LanC-like protein 2 | MGETMSKRLKFHLGEAEMEERSFPNPFPDYEAAASAAGLAAGSAEETGRVCPLPTTEDPGLPFHPNGKIVPNFIKRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTGDQTYLLRSLDYVKRTLRNLSGRRVTFLCGDAGPLAVGAVIYHKLKSECESQECITKLLQMHRTIVCQESELPDELLYGRAGYLYALLYLNTEIGPGTVGETAIKEVVSAIIESGKSLSREERKSERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPEAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHVLLQAYQVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTSGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAVHFLSDILVPETARFPAFELGFLQKD | Mouse | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp03651 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03652 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03653 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03654 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03655 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03656 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03657 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03663 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp03664 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03665 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp03666 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp03667 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp03668 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp03669 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp03705 | Latarcin 2a | GLFGKLIKKFGRKAISYAVKKARGKH | Central Asian spider | Membrane disruption | LDH leakage assay | Breast tumor cell line | Breast cancer | Not found |
| dbacp03706 | Latarcin 2a | GLFGKLIKKFGRKAISYAVKKARGKH-OH | Spider | Membrane disruption | Not specified | Not found | Not specified | Not found |
| dbacp04295 | ltc2aG11A | GLFGKLIKKFARKAISYAVKKARGKH | Central Asian spider | Membrane disruption | LDH leakage assay | Prostate tumor cell line | Prostate cancer | Not found |
| dbacp04442 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Blue-thighed frog, Australia | Cell membrane disruption | Not specified | Not found | Skin cancer | Not found |
| dbacp04453 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Blue-thighed frog, Australia | Cell membrane disruption | Not specified | Not found | Skin cancer | Not found |
| dbacp04476 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane disruption | WST-1 assay | HeLa | Pancreatic cancer | IC50 : > 60 µM |
| dbacp04498 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | Skin; Stomach, African clawed frog, Africa | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp04643 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :3.2 ± 0.1 µM |
| dbacp04644 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :2.1 ± 0.1 µM |
| dbacp04645 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :1.8 ± 0.1 µM |
| dbacp04646 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :1.4 ± 0.1 µM |
| dbacp04647 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Natural component of bee venom | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 1.4 ± 0.1 µM |
| dbacp04648 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Natural component of bee venom | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 3.2 ± 0.1 µM |
| dbacp04649 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Natural component of bee venom | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 2.1 ± 0.1 µM |
| dbacp04650 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Natural component of bee venom | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 1.8 ± 0.1 µM |
| dbacp04651 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Natural component of bee venom | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 1.4 ± 0.1 µM |
| dbacp04851 | NK-11 | KISKRILTGKK | NK2 derived iNot foundctive control peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : > 100 µM |
| dbacp04852 | NK-11 | KISKRILTGKK | NK2 derived iNot foundctive control peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : > 100 µM |
| dbacp04853 | NK-11 | KISKRILTGKK | NK2 derived iNot foundctive control peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : > 100 µM |
| dbacp04854 | NK-11 | KISKRILTGKK | NK2 derived iNot foundctive control peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : > 100 µM |
| dbacp04855 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 70 µM |
| dbacp04856 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM |
| dbacp04857 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM |
| dbacp04858 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 40 µM |
| dbacp04859 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Residue of 39-65 of porcine NK-lysine | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 4.3±0.3 µM |
| dbacp04860 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Residue of 39-65 of porcine NK-lysine | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 70 µM (approx.) |
| dbacp04861 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Residue of 39-65 of porcine NK-lysine | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM (approx.) |
| dbacp04862 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Residue of 39-65 of porcine NK-lysine | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM (approx.) |
| dbacp04863 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Residue of 39-65 of porcine NK-lysine | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 40 µM (approx.) |
| dbacp04880 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04881 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04882 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04883 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp05002 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp05003 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05004 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp05005 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp05006 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp05007 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp05008 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp05014 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp05015 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05016 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp05017 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp05018 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp05019 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp05020 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp05021 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 33 µMo/L |
| dbacp05022 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 17.8 µMo/L |
| dbacp05023 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.8 µMo/L |
| dbacp05024 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 11.1 µMo/L |
| dbacp05025 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 25.2 µMo/L |
| dbacp05026 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.7 µMo/L |
| dbacp05027 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 11.5 µMo/L |
| dbacp05028 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 10.4 µMo/L |
| dbacp05132 | Palustrin-Ca | MFTLKKSLLLLFFLGTISLSLCEQERDADGDEGEVEEVKRGFLDIIKDTGKEFAVKILNNLKCKLAGGCPP | American bullfrog | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp05221 | Pediocin PA-1/ AcH | KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGNHKC | Lactic acid bacteria | Cytoplasmic membrane disruption | Not specified | Not found | Human colorectal cancer | Not found |
| dbacp05405 | Peptide K14D | KWKSFLKTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.52 ± 0.05 µMol/L |
| dbacp05406 | Peptide K14D/K22D | KWKSFLKTFKSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.40 ± 0.09 µMol/L |
| dbacp05407 | Peptide K1D/K3D/K7D /K10D/K14D/K22D | kWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 18.07 ± 0.48 µMol/L |
| dbacp05408 | Peptide K22D | KWKSFLKTFKSLKKTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.39 ± 0.02 µMol/L |
| dbacp05409 | Peptide K3D/K7D /K10D/K14D/K22D | KWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 20.41 ± 0.64 µMol/L |
| dbacp05410 | Peptide K7D | KWKSFLkTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.29 ± 0.03 µMol/L |
| dbacp05411 | Peptide K7D /K10D/K14D/K22D | KWKSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.79 ± 0.23 µMol/L |
| dbacp05412 | Peptide K7D /K14D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.06 ± 0.01 µMol/L |
| dbacp05413 | Peptide K7D /K14D/K22D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.45 ± 0.19 µMol/L |
| dbacp05414 | Peptide L12D | KWKSFLKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.63 ± 0.07 µMol/L |
| dbacp05415 | Peptide L12D/L20D | KWKSFLKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.14 ± 0.06 µMol/L |
| dbacp05416 | Peptide L20D | KWKSFLKTFKSLKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.33 ± 0.06 µMol/L |
| dbacp05417 | Peptide L6D | KWKSFlKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.23 ± 0.10 µMol/L |
| dbacp05418 | Peptide L6D/L12D | KWKSFlKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.01 ± 0.08 µMol/L |
| dbacp05419 | Peptide L6D/L12D/L17D/L20D | KWKSFlKTFKSlKKTVlHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9.69 ± 0.38 µMol/L |
| dbacp05420 | Peptide L6D/L12D/L17D/L20D/L21D | KWKSFlKTFKSlKKTVlHTllKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 12.88 ± 0.15 µMol/L |
| dbacp05421 | Peptide L6D/L12D/L20D | KWKSFlKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7.80 ± 0.26 µMol/L |
| dbacp05427 | Peptide P | KWKSFLKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.71 ± 0.07 µMol/L |
| dbacp05433 | Peptide XT-7 | GLLGPLLKIAAKVGSNLL | Western clawed frog | Membrane disruption and cell lysis | Lactate dehydrogenase assay | HepG2 | Liver cancer | LD50 : 20 µM |
| dbacp05547 | Phylloseptin-PHa | FLSLIPAAISAVSALANHF | Skin secretions, Orange-legged Leaf Frog, South America | Membrane disruption | MTT cell viability assay | NCI-H157 | Lung cancer | IC50 : 14.10 μM |
| dbacp05554 | Phylloseptin-PTa | FLSLIPKIAGGIAALAKHL | Skin secretions, the Brown-bellied Leaf Frog, South America | Membrane disruption | MTT Cell viability assay | NCI-H157 | Lung cancer | IC50 : 6.73 μM |
| dbacp05587 | PNC-28 | ETFSDLWKLL | Ant | Membrane disruption | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | Cytotoxicity : 80µg/ml |
| dbacp05654 | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | MAATEGVGESAPGGEPGQPEQPPPPPPPPPAQQPQEEEMAAEAGEAAASPMDDGFLSLDSPTYVLYRDRAEWADIDPVPQNDGPSPVVQIIYSEKFRDVYDYFRAVLQRDERSERAFKLTRDAIELNAANYTVWHFRRVLLRSLQKDLQEEMNYIIAIIEEQPKNYQVWHHRRVLVEWLKDPSQELEFIADILNQDAKNYHAWQHRQWVIQEFRLWDNELQYVDQLLKEDVRNNSVWNQRHFVISNTTGYSDRAVLEREVQYTLEMIKLVPHNESAWNYLKGILQDRGLSRYPNLLNQLLDLQPSHSSPYLIAFLVDIYEDMLENQCDNKEDILNKALELCEILAKEKDTIRKEYWRYIGRSLQSKHSRESDIPASV | Rat | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp05866 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp05867 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05868 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp05869 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp05870 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp05871 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp05872 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp05875 | Ranatuerin-2-AW A6W, A10W | GFMKTWKNVWKNVAATLLKLLK | Sequence truncation, Amino acid substitution, animal-derived, natural derivative | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp05876 | Ranatuerin-2-AW D4K, D19K, K20L | GFMKTAKNVAKNVAATLLKLLK | Sequence truncation, Amino acid substitution, animal-derived, natural derivative | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp05914 | Raniseptin PL | GVFDTVKKIGKAVGKFALGVAKNYLNS | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | A549 | Not found | LC50 : < 30 μM |
| dbacp05915 | Raniseptin PL | GVFDTVKKIGKAVGKFALGVAKNYLNS | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | MDA-MB-231 | Not found | LC50 : < 30 μM |
| dbacp05916 | Raniseptin PL | GVFDTVKKIGKAVGKFALGVAKNYLNS | Skin secretions, the banana tree dwelling frog, Trinidad, South America | Membrane disruption | Not specified | HT29 | Not found | LC50 : < 30 μM |
| dbacp05921 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp05922 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05923 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp05924 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp05925 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp05926 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp05927 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp06079 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 99% Cytotoxicity at 4µM approx. |
| dbacp06080 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 95 % Cytotoxicity at 4µM approx. |
| dbacp06081 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 80% Cytotoxicity at 4µM |
| dbacp06082 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 100% Cytotoxicity at 4µM approx. |
| dbacp06083 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 90% Cytotoxicity at 4µM approx. |
| dbacp06084 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 70% Cytotoxicity at 5µM approx. |
| dbacp06085 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp06086 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp06087 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp06088 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp06089 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp06090 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp06091 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp06134 | Solute carrier family 15 member 2 | MNPFQQNESKETLFSPVSTEETPPRLSSPAKKTPPKICGSNYPLSIAFIVVNEFCERFSYYGMKAVLTLYFLYFLHWNEDTSTSVYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVNVLGHVIKSLSAFPILGGKVVHTVLSLVGLCLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSGFYLAINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKMYKKPPPEGNIVAQVVKCIWFAISNRFKNRSEDIPKRQHWLDWAAEKYPKQLIMDVKTLTRVLFLYIPLPMFWALLDQQGSRWTLQATKMNGNLGFFVLQPDQMQVLNPLLVLIFIPLFDLVIYRLISKCGINFTSLRKMAVGMVLACLAFAAAATVEIKINEMAPPQPGSQEILLQVLNLADDEVKLTVLGNNNNSLLADSIKSFQKTPHYSKIHLNTKSQDFYFHLKYHNLSIYTEHSVEERNWYSLIIREDGKSISSIMVKDMENETTYGMTAIRFINTLQENVNISLGTDISLNVGENYGVSAYRTVQRGEYPAVHCKTEDKDFSLNLGLLDFGASYLFVITNSTKQGLQAWKMEDIPANKVSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTVAIGNIIVLVVAQFSGLVQWAEFVLFSCLLLVVCLIFSIMGYYYIPIKSEDIQGPEDKQIPHMQGnMINLETKKTKL | Rabbit | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp06135 | Solute carrier family 15 member 2 | MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGnMIKLETKKTKL | Human | Membrane disruption | Not specified | U87 | Glioblastoma | Not found |
| dbacp06136 | Solute carrier family 15 member 2 | MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGnMIKLETKKTKL | Human | Membrane disruption | Not specified | T98G | Glioblastoma | Not found |
| dbacp06137 | Solute carrier family 15 member 2 | MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGnMIKLETKKTKL | Human | Membrane disruption | Not specified | LN405 | Glioblastoma | Not found |
| dbacp06138 | Solute carrier family 15 member 2 | MNPFQKNESKETLFSPVSTEEMLPRPPSPPKKSPPKIFGSSYPVSIAFIVVNEFCERFSYYGMKAVLTLYFLYFLHWNEDTSTSVYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVFKSLGAIPILGGKMLHTILSLVGLSLIALGTGGIKPCVAAFGGDQFEEEHAEARTRYFSVFYLAINAGSLISTFITPMLRGDVKCFGQDCYALAFGVPGLLMVLALVVFAMGSKMYRKPPPEGNIVAQVIKCIWFALCNRFRNRSGDLPKRQHWLDWAAEKYPKHLIADVKALTRVLFLYIPLPMFWALLDQQGSRWTLQANKMNGDLGFFVLQPDQMQVLNPFLVLIFIPLFDLVIYRLISKCRINFSSLRKMAVGMILACLAFAVAALVETKINGMIHPQPASQEIFLQVLNLADGDVKVTVLGSRNNSLLVESVSSFQNTTHYSKLHLEAKSQDLHFHLKYNSLSVHNDHSVEEKNCYQLLIHQDGESISSMLVKDTGIKPANGMAAIRFINTLHKDLNISLDTDAPLSVGKDYGVSAYRTVLRGKYPAVHCETEDKVFSLDLGQLDFGTTYLFVITNITSQGLQAWKAEDIPVNKLSIAWQLPQYVLVTAAEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTVAVGNIIVLVVAQFSGLAQWAEFVLFSCLLLVVCLIFSVMAYYYVPLKSEDTREATDKQIPAVQGnMINLETKNTRL | Rat | Membrane disruption via electrochemical proton gradient | Not specified | Not found | Not found | Not found |
| dbacp06144 | Ss-arasin | MERTLLIVLLVCFLLLAVTAEA | The Indian mud crab | Membrane disruption by pore-formation or by permeating the membrane and acting on intracellular targets | MTT assay | HeLa | Human cervical carcinoma | IC 50 : 3.06 μM |
| dbacp06145 | Ss-arasin | MERTLLIVLLVCFLLLAVTAEA | The Indian mud crab | Membrane disruption by pore-formation or by permeating the membrane and acting on intracellular targets | MTT assay | HT-29 | Colon carcinoma | IC 50 : 2.90 μM |
| dbacp06146 | Ss-arasin | SPRVRRRYGRPFGGRPFVGGQFGGRPGCVCIRSPCPCANYG | The Indian mud crab | Membrane disruption by pore-formation or by permeating the membrane and acting on intracellular targets | MTT assay | HT-29 | Human cervical carcinoma | IC 50 : 2.90 μM |
| dbacp06147 | Ss-arasin | SPRVRRRYGRPFGGRPFVGGQFGGRPGCVCIRSPCPCANYG | The Indian mud crab | Membrane disruption by pore-formation or by permeating the membrane and acting on intracellular targets | MTT assay | HeLa | Colon carcinoma | IC 50 : 3.06 μM |
| dbacp06222 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 70% Cell viability at 20 µM |
| dbacp06223 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 45% Cell viability at 30 µM |
| dbacp06224 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 30 % Cell viability at 40 µM |
| dbacp06231 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MDA-MB-231 | Breast cancer | 22% cell viability at 40 µM |
| dbacp06232 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MDA-MB-231 | Breast cancer | 61% cytotoxicity at 40 µM |
| dbacp06233 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | 61% cell viability at 40 µM |
| dbacp06234 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MCF-7 | Breast cancer | 32% cytotoxicity at 40 µM |
| dbacp06235 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MDA-MB-231 | Breast cancer | MIC : 40 µM |
| dbacp06236 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MDA-MB-231 | Breast cancer | MIC : 40 µM |
| dbacp06237 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | MIC : 40 µM |
| dbacp06238 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MCF-7 | Breast cancer | MIC : 40 µM |
| dbacp06351 | Tritrpticin | VRRFPWWWPFLRR | Pig | Membrane disruption | MIC assay | Not found | Not found | MIC : 2 mM |
| dbacp06413 | U1-TRTX-Ar1b | SCVYERETCSKVRGPLCCRGECTCPIYGDCFCYGS-OHc | Spider (Theraphosidae family) | Membrane disruption | Not specified | Not found | Not specified | Not found |
| dbacp06414 | U1-TRTXAgm3a | ACGSFMWKCSERLPCCQEYVCSPQWKWCQNP-OHa | Spider (Theraphosidae family) | Membrane disruption | Not specified | Not found | Not specified | Not found |
| dbacp06423 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | HaCat | Not specified | Not found |
| dbacp06424 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp06425 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | K562 | Not specified | Not found |
| dbacp06426 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | HEK293 | Not specified | Not found |
| dbacp06427 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | Namalwa | Not specified | Not found |
| dbacp06428 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | U937 | Not specified | Not found |
| dbacp06429 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | HeLa | Not specified | Not found |
| dbacp06861 | LK-LE1 | CLKKLLKLLKKLLKLCLHELLEHLHELLEH | Synthetic | Membrane disruption | MTT assay | HeLa | Cervical Cancer | IC50 = 11.3 µM at pH 6 |
| dbacp06862 | LK-LE2 | CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH | Synthetic | Membrane disruption | MTT assay | HeLa | Cervical Cancer | IC50 = 12.9 µM at pH 6 |
| dbacp06863 | LK-LE3 | CLKKLLKLLKKLLKLCLEELLHHLEELLHH | Synthetic | Membrane disruption | MTT assay | HeLa | Cervical Cancer | IC50 = 10.2 µM at pH 6 |
| dbacp07021 | BmPLA2 | FKWQFEMLIMKIAKTSGFMFYSSY | phospholipase A2 isoform from B. moojeni venom | Membrane disruption, selective cancer cytotoxicity | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 0.6 µM |
| dbacp07022 | BmPLA2 | FKWQFEMLIMKIAKTSGFMFYSSY | phospholipase A2 isoform from B. moojeni venom | Membrane disruption, selective cancer cytotoxicity | MTT assay | RD | Rhabdomyosarcoma | 60% reduction in cell viability |
| dbacp07097 | K2F6K2 | KKFFFFFFKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 1146.23 ± 346.83 μg/mL |
| dbacp07098 | K3F6K3 | KKKFFFFFFKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 123.10 ± 35.19 μg/mL |
| dbacp07099 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 62.64 ± 9.55 μg/mL |
| dbacp07100 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | AnnexinV-FITC/PI double staining assay | A-549 | Lung Cancer | apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13% |
| dbacp07101 | K4F8K4 | KKKKFFFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 571.87 ± 66.23 μg/mL |
| dbacp07102 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | H-460 | Lung Cancer | IC50 = 6.27 µM |
| dbacp07103 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | HepG-2 | Liver Cancer | IC50 = 441.01 µM |
| dbacp07104 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | T-24 | Urinary Bladder Cancer | IC50 = 1.94 x 105 µM |
| dbacp07105 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | DU-145 | Prostate cancer | IC50 = 1158.30 µM |
| dbacp07106 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | HeLa | Cervical cancer | IC50 = 3.34 x 104 µM |
| dbacp07107 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | H-157 | Non-small cell lung cancer | IC50 = 24 μM |
| dbacp07108 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | PC-3 | Prostate cancer | IC50 = 31.27 μM |
| dbacp07109 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | U-251-MG | Brain Tumor | IC50 = 25.06 μM |
| dbacp07110 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | MCF-7 | Breast Cancer | IC50 = 24.60 μM |
| dbacp07259 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 18.99 μM |
| dbacp07260 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 10.11 μM |
| dbacp07261 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 6.143 μM |
| dbacp07262 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | U251-MG | Brain Tumor | IC50 = 32.18 μM |
| dbacp07263 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.605 μM |
| dbacp07264 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 1.796 μM |
| dbacp07265 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 1.546 μM |
| dbacp07266 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | U251-MG | Brain Tumor | IC50 = 2.679 μM |
| dbacp07267 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 55.65 μM |
| dbacp07268 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 186.1 μM |
| dbacp07269 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 88.28 μM |
| dbacp07270 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | U251-MG | Brain Tumor | IC50 = 593.7 μM |
| dbacp07271 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 118.4 μM |
| dbacp07272 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 180.8 μM |
| dbacp07273 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 427.3 μM |
| dbacp07274 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | U251-MG | Brain Tumor | IC50 = 1499 μM |
| dbacp07336 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | NCI-H23 | Lung Cancer | IC50 = 4.96 ± 0.94 μM |
| dbacp07337 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | H-157 | Lung Cancer | IC50 = 15.18 ± 2.98 μM |
| dbacp07338 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | H-460 | Lung Cancer | IC50 = 1.64 ± 0.41 μM |
| dbacp07397 | Pugnin A | RLMRIFRILKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | 12% Cytotoxicity at 100 µM |
| dbacp07398 | Pugnin A | RLMRIFRILKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 74% Cytotoxicity at 100 µM |
| dbacp07399 | Pugnin B | RMMRIFWVIKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | 5% Cytotoxicity at 100 µM |
| dbacp07400 | Pugnin B | RMMRIFWVIKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 90% Cytotoxicity at 100 µM |
| dbacp07402 | Pep | GKLRLIKKLWVKKWKKKGWKA | Synthetic | Membrane disruption induces necrotic death | MTT assay | A-549 | Lung Cancer | IC50 = 4 µM |
| dbacp07403 | Pep | GKLRLIKKLWVKKWKKKGWKA | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | IC50 = 2 µM |
| dbacp07408 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | U251-MG | Brain Tumor | Graph Figure-7 |
| dbacp07409 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | H-157 | Lung Cancer | Graph Figure-7 |
| dbacp07410 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | PC-3 | Prostate Cancer | Graph Figure-7 |
| dbacp07411 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 124.1 ± 8.12 µM |
| dbacp07412 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 746.5 ± 7.6 µM |
| dbacp07413 | Si3 | KL(Beta-A)KL(Beta-A)AK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 176.3 ± 4.66 µM |
| dbacp07414 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 662.9 ± 20.02 µM |
| dbacp07415 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 840 ± 21.18 µM |
| dbacp07416 | Si11 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1087 ± 70.71 µM |
| dbacp07417 | Si11 | KL(Beta-A)KLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 228.8 ± 7.18 µM |
| dbacp07418 | Si13 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 1704 ± 112 µM |
| dbacp07419 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 593.3 ± 60.3 µM |
| dbacp07420 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1049 ± 49.77 µM |
| dbacp07421 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 140.3 ± 7.12 µM |
| dbacp07422 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 346.3 ± 7.91 µM |
| dbacp07432 | [Arg]3-VmCT1 | FLRALWNVAKSVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 20.6 ± 3.1 μmol/L |
| dbacp07433 | [Arg]7-VmCT1 | FLGALWRVAKSVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 18.0 ± 2.7 μmol/L |
| dbacp07434 | [Arg]11-VmCT1 | FLGALWNVAKRVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.8 ± 5.2 μmol/L |
| dbacp07435 | L9H5-1 | LHLLLHLLHHLLHL | Synthetic | Acid-triggered membrane disruption apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 5.4 µM |
| dbacp07436 | L8H6 | LHHLLHLLHHLLHL | Synthetic | Acid-triggered membrane disruption apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 16.4 µM |
| dbacp07465 | ΔM4 | NFFKRIRRAWKRIWKWIYSA | Synthetic | Membrane disruption triggers mitochondrial apoptosis | Not Available | A-375 | Skin Cancer | IC50 = 9.31 μM |
| dbacp07491 | Figainin 1 | FIGTLIPLALGALTKLFK | Boana raniceps | Membrane disruption, α-helix mediated | MTT assay | MCF-7 | Breast Cancer | IC50 = 13.7 µM |
| dbacp07492 | Figainin 1 | FIGTLIPLALGALTKLFK | Boana raniceps | Membrane disruption, α-helix mediated | MTT assay | HeLa | Cervical Cancer | IC50 = 11.1 µM |
| dbacp07493 | Figainin 1 | FIGTLIPLALGALTKLFK | Boana raniceps | Membrane disruption, α-helix mediated | MTT assay | B16-F10 | Skin Cancer | IC50 = 10.5 µM |
| dbacp07512 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | H-157 | Lung Cancer | IC50 = 1.55 μM |
| dbacp07513 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 2.92 μM |
| dbacp07514 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 4.15 μM |
| dbacp07515 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | U-251 | Brain Tumor | IC50 = 2.47 μM |
| dbacp07516 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | LDH leakage assay | H-157 | Lung Cancer | 80% LDH release at 10−4 M |
| dbacp07849 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.44 µM |
| dbacp07850 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | U251-MG | Brain Tumor | IC50 = 49.51 µM |
| dbacp07851 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | H-157 | Lung Cancer | IC50 = 25.51 µM |
| dbacp07852 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 21.78 µM |
| dbacp07853 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 28.95 µM |
| dbacp07854 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | MCF-7 | Breast Cancer | IC50 = 8.64 µM |
| dbacp07855 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | U251-MG | Brain Tumor | IC50 = 18.51 µM |
| dbacp07856 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | H-157 | Lung Cancer | IC50 = 9.88 µM |
| dbacp07857 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 9.97 µM |
| dbacp07858 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 11.17 µM |
| dbacp07877 | Fi-Histin1-21 | SRSSRAGLQFPVGRIHRLLRK | Fenneropenaeus indicus | Membrane disruption and DNA binding | XTT assay | NCI-H-460 | Lung Cancer | IC50 = 22.670 ± 13.939 μM |
| dbacp07878 | Fi-Histin1-21 | SRSSRAGLQFPVGRIHRLLRK | Fenneropenaeus indicus | Membrane disruption and DNA binding | XTT assay | Hep-2 | Liver Cancer | IC50 = 31.274 ± 24.531 μM |
| dbacp07926 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | MDA-MB-435S | Breast Cancer | IC50 = 208 µM |
| dbacp07927 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | H-838 | Lung Cancer | Cell viability ~ 65% at 10-5 M |
| dbacp07934 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | U-87-MG | Brain Tumor | IC50 = 29.20 ± 7.96 µM |
| dbacp07935 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | U-373-MG | Brain Tumor | IC50 = 20.94 ± 5.18 µM |
| dbacp07936 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | SH-SY5Y | Brain Tumor | IC50 = 93.80 ± 2.17 µM |
| dbacp07937 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 28.5 ± 1.0 µM |
| dbacp07938 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 47.5 ± 2.0 µM |
| dbacp07939 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 12.5 ± 1.0 µM |
| dbacp07940 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 16.5 ± 1.0 µM |
| dbacp07941 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 13.5 ± 2.0 µM |
| dbacp07942 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 17.3 ± 1.0 µM |
| dbacp07945 | Emericellipsin A | (3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine | Emericellopsis alkalina | Membrane disruption, antifungal, antibacterial, anticancer | MTT assay | HepG-2 | Liver Cancer | EC50 = 2.8 uM |
| dbacp07946 | Emericellipsin A | (3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine | Emericellopsis alkalina | Membrane disruption, antifungal, antibacterial, anticancer | MTT assay | HeLa | Cervical Cancer | EC50 < 0.5 uM |
| dbacp08089 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 17.9 ± 1.4 μM |
| dbacp08090 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 15.7 ± 1.5 μM |
| dbacp08091 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 18.2 ± 1.3 μM |
| dbacp08092 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 19.1 ± 2.1 μM |
| dbacp08093 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 33.6 ± 4.2 μM |
| dbacp08094 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 30.8 ± 3.4 μM |
| dbacp08095 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 36.1 ± 6.7 μM |
| dbacp08096 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 39.6 ± 5.7 μM |
| dbacp08097 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 47.4 ± 12.5 μM |
| dbacp08098 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.3 ± 3.2 μM |
| dbacp08099 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.4 ± 3.1 μM |
| dbacp08100 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 26.5 ± 1.5 μM |
| dbacp08101 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 27.3 ± 2.4 μM |
| dbacp08102 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.2 ± 2.7 μM |
| dbacp08103 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 28.3 ± 2.3 μM |
| dbacp08104 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 19.2 ± 2.3 μM |
| dbacp08105 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 18.4 ± 1.5 μM |
| dbacp08106 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 20.7 ± 1.6 μM |
| dbacp08107 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 22.7 ± 2.3 μM |
| dbacp08108 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 60.7 ± 5.4 μM |
| dbacp08109 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 38.3 ± 2.5 μM |
| dbacp08110 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 30.6 ± 5.7 μM |
| dbacp08111 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 83.7 ± 5.3 μM |